Management of Mast Cell Activation Syndrome with Proctocolitis

Initial Pharmacologic Approach

The American Academy of Allergy, Asthma, and Immunology recommends starting with non-sedating H1 antihistamines (fexofenadine or cetirizine) at 2-4 times FDA-approved doses to control systemic symptoms including tachycardia, flushing, and abdominal discomfort 1, 3, 4
The American Gastroenterological Association suggests adding H2 receptor antihistamines immediately for gastrointestinal symptoms, as they work synergistically with H1 blockers and specifically target gastric hypersecretion 1, 3, 4

The American Gastroenterological Association recommends following standard DGBI diagnostic strategies using positive symptom-based diagnosis with limited noninvasive testing 2
The American Gastroenterological Association suggests performing anorectal manometry, balloon expulsion test, or defecography if symptoms include incomplete evacuation, as pelvic floor dysfunction (particularly rectal hyposensitivity) is highly prevalent in this population 2
The American Gastroenterological Association recommends considering celiac disease testing earlier in the evaluation given the variety of GI symptoms 2

The American Gastroenterological Association recommends using loperamide, bile acid sequestrants (cholestyramine, colestipol, colesevelam), eluxadoline, or 5-HT3 antagonists (alosetron) for diarrhea 2
The American Gastroenterological Association suggests trialing osmotic/stimulant laxatives, lubiprostone, guanylate cyclase-C agonists (linaclotide, plecanatide), prucalopride, or tenapanor for constipation 2
The American Gastroenterological Association recommends considering antispasmodics (hyoscyamine, dicyclomine, peppermint oil) or neuromodulators (tricyclic antidepressants, SSRIs, SNRIs, pregabalin, gabapentin) depending on pain characteristics for abdominal pain 2

The American Gastroenterological Association recommends avoiding opiates entirely for abdominal pain management in this population 2

The American Academy of Allergy, Asthma, and Immunology suggests using cyproheptadine (sedating H1 blocker with antiserotonergic properties) specifically for diarrhea and nausea 1, 3
The American Academy of Allergy, Asthma, and Immunology recommends using leukotriene inhibitors (montelukast or zileuton) to reduce GI symptoms, particularly if urinary LTE4 levels are elevated 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends considering omalizumab for prevention of anaphylactic episodes 1, 3
The American Academy of Allergy, Asthma, and Immunology suggests using short-term corticosteroid burst (0.5 mg/kg/day prednisone with slow taper over 1-3 months) for refractory symptoms, but avoiding long-term use due to side effects 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends prescribing epinephrine autoinjectors with training on use for any history of systemic anaphylaxis or airway angioedema 1, 4
The American Academy of Allergy, Asthma, and Immunology suggests providing supine positioning training for hypotensive episodes 1, 4
The American Academy of Allergy, Asthma, and Immunology recommends prescribing albuterol inhalers for bronchospasm 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends avoiding first-generation H1 antihistamines (diphenhydramine, hydroxyzine) long-term in elderly patients due to cognitive decline risk and cardiovascular concerns 1, 4
The American Academy of Allergy, Asthma, and Immunology suggests introducing all medications cautiously in controlled settings, as paradoxical mast cell activation can occur 3, 4
The American Academy of Allergy, Asthma, and Immunology recommends not relying on dietary restriction alone without pharmacologic management—this is insufficient and not guideline-recommended 4, 5

The American Academy of Allergy, Asthma, and Immunology recommends guiding therapy by symptoms and elevated mast cell mediator levels rather than arbitrary timelines 4
The American Gastroenterological Association suggests considering multidisciplinary care given the multisystemic nature of MCAS and overlapping conditions 2